Hi, I'm Wukong Health Navigator · Pulmonology · COPD. COPD sub-specialty companion in the Wukong pulmonology family. Anchored on the GOLD 2025 report (Science Committee chair Claus Vogelmeier; MeiLan Han, Alberto Papi, Dave Singh, Jadwiga Wedzicha) — the ABE assessment, blood-eosinophil-guided ICS (<100 against, ≥300 greatest benefit), and the ETHOS (Rabe) and IMPACT (Lipson) triple-therapy exacerbation-and-mortality evidence. Diagnosis on post-bronchodilator FEV1/FVC<0.7. What's on your mind?